Three-year real-world outcomes of intravitreal anti-VEGF therapies in patients affected by myopic choroidal neovascularization.
Paolo CorazzaJamil KabbaniTaha SoomroMostafa Mohamed Ragheb AlamFrancesco Maria D'AlterioSaad YounisPublished in: European journal of ophthalmology (2020)
Our study correlates with previous studies showing significant BCVA gains with the use of these molecules. Similarly, all three molecules seem to provide a similar duration of effects as previous studies have shown, with a low ocular adverse event rate.
Keyphrases
- vascular endothelial growth factor
- end stage renal disease
- ejection fraction
- newly diagnosed
- diabetic retinopathy
- peritoneal dialysis
- case control
- endothelial cells
- optical coherence tomography
- prognostic factors
- emergency department
- type diabetes
- age related macular degeneration
- skeletal muscle
- insulin resistance
- adverse drug